Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy

…, E Hjerpe, S Leskelä, C Jara, X Mielgo… - Journal of medical …, 2013 - jmg.bmj.com
Background Peripheral neuropathy is the dose limiting toxicity of paclitaxel, a
chemotherapeutic drug widely used to treat solid tumours. This toxicity exhibits great inter-individual …

A phase III clinical trial of adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients …

…, P Martín-Martorell, J Bosch-Barrera, X Mielgo… - 2021 - ascopubs.org
TPS8581 Background: The results of current studies are considered acceptable evidence to
support the hypothesis of efficacy of the proposed combination of immunotherapy with …

[HTML][HTML] Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from …

…, J Coves, R Blanco, J Balsalobre, X Mielgo… - European Journal of …, 2021 - Elsevier
Background Survival data support the use of first-line osimertinib as the standard of care for
epidermal growth factor receptor (EGFR)–positive non-small cell lung cancer (NSCLC). …

[HTML][HTML] Immunotherapy in non-small cell lung cancer: Update and new insights

X Mielgo-Rubio, EA Uribelarrea, LQ Cortés… - Journal of clinical and …, 2021 - ncbi.nlm.nih.gov
… Xabier Mielgo-Rubio declares the following conflicts of interest: Advisory role; Boehringer-Ingelheim,
Astra Zeneca, Brystol Myers Squibb. Speakers’ bureau; Roche, Astra Zeneca, …

Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer

…, M Sereno, LF Franco, X Mielgo… - European …, 2018 - Eur Respiratory Soc
… Pilar Ochoa, Rafael López Castro, Berta Obispo, Cristina Pangua, María Sereno,
Lourdes Fernández Franco, Xabier Mielgo, Julia Calzas, Ana Blasco, Francisco Aparisi …

[HTML][HTML] A multicenter analysis of the outcome of cancer patients with neutropenia and COVID-19 optionally treated with granulocyte-colony stimulating factor (G-CSF) …

…, J Baena-Espinar, C Aguado, X Mielgo… - Cancers, 2021 - mdpi.com
Simple Summary Infections with COVID-19 in neutropenic cancer patients are related to poor
outcomes. A G-CSF treatment used in neutropenic cancer with SARS-CoV-2 infections is …

[HTML][HTML] High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1

…, R López, M Sereno, X Mielgo… - European Journal of …, 2020 - Elsevier
Introduction Based on the high incidence of thromboembolic events (TEs) observed in lung
adenocarcinomas with ALK translocations and taking into account the biological proximity of …

Brain metastases from non-small cell lung carcinoma: an overview of classical and novel treatment strategies

…, C Vallejo, L Guerrero, X Mielgo… - reports of Practical …, 2022 - journals.viamedica.pl
Background: The development of brai nm etastases is a common problem in patients diagnosed
with no ns mall cell lung carcinoma (NSCLC). Technological advances in surgery and …

[HTML][HTML] New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer

…, JL Fírvida, R Chicas-Sett, X Mielgo… - World Journal of …, 2021 - ncbi.nlm.nih.gov
Immunotherapy has represented one of the main medical revolutions of recent decades,
and is currently a consolidated treatment for different types of tumors at different stages and …

Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma

…, R Blanco, E Gálvez, A Insa, X Mielgo… - Clinical and …, 2021 - Springer
Background Anti-angiogenic agents are reported to exert clinical activity in patients with
epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). We …